Brooks Laboratories Ltd

At Rs 64.05, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 19.99% on 6 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and technical outlook.

At Rs 44.53, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 19.99% on 1 Apr 2026, with buyers queuing and no sellers willing to part with shares.

While broader indices have shown signs of recovery, Brooks Laboratories Ltd has continued its downward trajectory, hitting a fresh 52-week low of Rs 40 on 30 Mar 2026. The stock’s recent performance starkly contrasts with the market’s modest rebound, underscoring persistent challenges specific to the company.

A sharp decline of 5.28% today dragged Brooks Laboratories Ltd to a fresh 52-week low of Rs 44.47, extending a downward trend that has seen the stock lose over 60% in the past year despite pockets of financial improvement.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

For the third consecutive session, Brooks Laboratories Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 50.6 on 23 Mar 2026. This marks a significant 58.42% drop over the past year, sharply underperforming the broader Sensex, which itself is nearing its own 52-week low.

Brooks Laboratories Ltd’s stock price declined to a fresh 52-week low of Rs.53.75 on 20 March 2026, marking a significant downturn amid broader market movements. The stock has underperformed its sector and key benchmarks, reflecting ongoing concerns about its financial metrics and market positioning.

Brooks Laboratories Ltd’s shares declined sharply to a new 52-week low of Rs.54.2 on 19 Mar 2026, marking a significant drop amid broader market weakness and sectoral pressures. The stock underperformed the Pharmaceuticals & Biotechnology sector and the wider market, reflecting ongoing concerns about its long-term performance and valuation metrics.

Brooks Laboratories Ltd has touched a new 52-week low of Rs.54.62 today, marking a significant decline in its stock price amid broader market movements. The stock has underperformed its sector and key benchmarks, reflecting ongoing concerns about its financial metrics and market positioning.

Brooks Laboratories Ltd has touched a new 52-week low of Rs.57 today, marking a significant decline amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting persistent pressures on its valuation and performance metrics.

Brooks Laboratories Ltd has reached a new 52-week low of Rs.57.06, marking a significant decline in its stock price amid broader market weakness and sector underperformance. The stock’s recent performance reflects ongoing challenges in its financial metrics and market positioning within the Pharmaceuticals & Biotechnology sector.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Brooks Laboratories Ltd has reached a new 52-week low of Rs.57.84, marking a significant decline amid broader market weakness and ongoing challenges within the Pharmaceuticals & Biotechnology sector. The stock’s recent performance reflects a continuation of downward momentum, with a three-day losing streak culminating in a 5.27% drop over this period.

Brooks Laboratories Ltd has reached a new 52-week low of Rs.58.25 today, marking a significant decline in its share price amid ongoing market pressures and a series of underwhelming performance metrics. The stock’s recent trajectory reflects a challenging period for the company within the Pharmaceuticals & Biotechnology sector.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Brooks Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change, coupled with its current financial metrics and market performance, offers investors a nuanced perspective on the stock’s price attractiveness relative to its historical averages and peer group.